BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34044811)

  • 21. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
    Aksenenko MB; Kirichenko AK; Ruksha TG
    Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
    Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
    Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of BRAF mutations in localized cutaneous melanoma.
    Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
    J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational profiling of acral melanomas in Korean populations.
    Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
    Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.
    Ny L; Hernberg M; Nyakas M; Koivunen J; Oddershede L; Yoon M; Wang X; Guyot P; Geisler J
    Acta Oncol; 2020 Jul; 59(7):833-844. PubMed ID: 32285732
    [No Abstract]   [Full Text] [Related]  

  • 29. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
    Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
    J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.
    Kim SY; Kim SN; Hahn HJ; Lee YW; Choe YB; Ahn KJ
    J Am Acad Dermatol; 2015 Jun; 72(6):1036-46.e2. PubMed ID: 25819940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
    Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
    Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
    Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
    J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
    Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
    Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.
    Cheung CHY; Cheng CK; Lau KM; Ip RKL; Chan NCN; Tam THC; Wong RSM; Raghupathy R; Chan NPH; Ng MHL
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e315-e325. PubMed ID: 29807803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
    Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
    Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
    Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.